Loading
companiesCompany
RayzeBio (BMS)
RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.
Overview
RayzeBio, based in San Diego, is the actinium-225 radiopharmaceutical company that Bristol Myers Squibb bought for 4.1 billion dollars, and its RYZ101 is in phase 3. RYZ101 is actinium-225 DOTATATE for somatostatin-receptor-positive neuroendocrine tumours, RYZ801 is an actinium-225 PSMA agent, and the company built in-house actinium-225 manufacturing. OnCo links it to neuroendocrine tumours, to peptide receptor radionuclide therapy and targeted alpha therapy, to the actinium-225 DOTATATE drug record, and to the radiopharmaceutical roadmap from iodine through lutetium to actinium. Whether an alpha emitter can improve on lutetium-based radioligand therapy is the question RYZ101's phase 3 will answer. Actinium-225 DOTATATE has its own page.
Headquarters
San Diego, CA, US
Scorecard
All companies#403of 1244 companies, score 9
- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-12-26 | RayzeBio (BMS) to Bristol Myers Squibb RYZ101 (actinium-225 DOTATATE) and an actinium-based radiopharmaceutical platform | Acquisition | not disclosed | $4.1bn | source |
Website
Phase 3Targeted alpha therapy
An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version.
Similar pages
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 DOTATATE, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- CompanyOrano Med
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- CompanyTerraPower Isotopes
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- TrialACTION-1
Shares Actinium-225 DOTATATE, Targeted alpha therapy, Neuroendocrine tumours.
- Treatment212Pb-DOTAMTATE
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- CompanyFusion Pharmaceuticals (AstraZeneca)
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- TrialALPHAMEDIX-02
Shares Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
cancers
fronts
technologies
drugs
Phase 3Targeted alpha therapy